Cargando…

High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens

The prognostic significance of tumor-associated macrophages (TAMs) in multiple myeloma (MM) in the era of novel drugs remains unclear. CD163 expression was detected by immunohistochemistry to determine the number of TAMs in 198 MM patients receiving bortezomib-based regimens and the data were used t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hua, Hu, Wan-ming, Xia, Zhong-jun, Liang, Yang, Lu, Yue, Lin, Shu-xia, Tang, Hailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603386/ https://www.ncbi.nlm.nih.gov/pubmed/31289595 http://dx.doi.org/10.7150/jca.30102

Ejemplares similares

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma
por: Salmi, Satu, et al.
Publicado: (2019)

CD47 expression and CD163(+) macrophages correlated with prognosis of pancreatic neuroendocrine tumor
por: Imam, Rami, et al.
Publicado: (2021)

CD163+ Tumor-Associated Macrophages Correlated with Poor Prognosis and Cancer Stem Cells in Oral Squamous Cell Carcinoma
por: He, Ke-Fei, et al.
Publicado: (2014)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
por: Ataca Atilla, Pınar, et al.
Publicado: (2019)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages
por: Hu, Wan-Ming, et al.
Publicado: (2020)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

High Numbers of CD163-Positive Macrophages in the Fibrotic Region of Exuberant Granulation Tissue in Horses
por: Du Cheyne, Charis, et al.
Publicado: (2021)

High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
por: Li, Philippa, et al.
Publicado: (2021)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Targeting of CD163(+) Macrophages in Inflammatory and Malignant Diseases
por: Skytthe, Maria K., et al.
Publicado: (2020)

PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA
por: MA, Naya, et al.
Publicado: (2023)

The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma
por: Kong, Ling-Qun, et al.
Publicado: (2013)

CD163 as a marker of M2 macrophage, contribute to predict aggressiveness and prognosis of Kazakh esophageal squamous cell carcinoma
por: Hu, Jian Ming, et al.
Publicado: (2017)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015)

Drug Trafficking into Macrophages via the Endocytotic Receptor CD163
por: Graversen, Jonas Heilskov, et al.
Publicado: (2015)

Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib
por: Camiolo, Giuseppina, et al.
Publicado: (2020)

Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
por: Chim, Chor Sang, et al.
Publicado: (2012)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Elevated CD163(+)/CD68(+) Ratio at Tumor Invasive Front is Closely Associated with Aggressive Phenotype and Poor Prognosis in Colorectal Cancer
por: Yang, Chaogang, et al.
Publicado: (2019)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma
por: Swan, Christopher D., et al.
Publicado: (2014)

Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of ‘soluble CD163’ in plasma
por: Etzerodt, Anders, et al.
Publicado: (2017)

Haptoglobin Genotype-Dependent Anti-Inflammatory Signaling in CD163(+) Macrophages
por: Landis, R. Clive, et al.
Publicado: (2013)

Distinct Profiles of CD163-Positive Macrophages in Idiopathic Interstitial Pneumonias
por: Yamashita, Masahiro, et al.
Publicado: (2018)

Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer
por: Xue, Tao, et al.
Publicado: (2021)

Dexamethasone enhances CD163 expression in porcine IPKM immortalized macrophages
por: Takenouchi, Takato, et al.
Publicado: (2021)

CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma
por: Harris, Jonathan A, et al.
Publicado: (2012)

Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
por: Nielsen, Marlene Christina, et al.
Publicado: (2020)

Prophylaxis of decidual CD68(+)/CD163(+) macrophage disbalance in extracorporeal fertilized women
por: Likhachov, Volodymyr, et al.
Publicado: (2023)

Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis
por: Vaht, Krista, et al.
Publicado: (2022)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma
por: Hu, Xiaotong, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aaounfgekfgqi1fq5808hb7hco